JV

John Volpone

President, Chief Operating Officer

X4 Pharmaceuticals

X4 Pharmaceuticals Pipeline

DrugIndicationPhase
XOLREMDI® (mavorixafor)WHIM syndrome (patients 12 years and older)Approved
MavorixaforChronic Neutropenic DisordersPhase 3